Table 2 Differences in neoplasm-related deaths between SSc patients and the general Spanish population during 2016–2019
From: Neoplasm related mortality risk in Systemic Sclerosis: a nationwide study
Neoplasm-related deaths N (%) | Mean age (years), (SD) | |||||
|---|---|---|---|---|---|---|
Non-SSc | SSc | p | Non-SSc | SSc | p | |
Total | 139,464 | 67 | - | 70.7 (13.5) | 67.6 (12.5) | 0.058 |
SON | 127,091 (91.1) | 62 (92.5) | 0.832 | 70.6 (13.3) | 67.7 (12.3) | 0.09 |
HN | 12,373 (8.9) | 5 (7.5) | 0.832 | 71.9 (15.5) | 65.8 (16) | 0.381 |
Malign neoplasm | 136,815 (98.1) | 67 (100) | 0.641 | 70.6 (13.5) | 67.6 (12.2) | 0.067 |
Malign SON | 124,841 (89.5) | 62 (92.5) | 0.550 | 70.5 (13.3) | 67.8 (12.3) | 0.100 |
Malign HN | 12,002 (8.6) | 5 (7.5) | 1 | 71.7 (15.6) | 65.8 (16) | 0.401 |
Benign SON | 727 (0.5) | 0 | 1 | 72.3 (13.5) | - | - |
UB neoplasm | 1,698 (1.2) | 0 | 1 | 78.7 (13.8) | - | - |
UB SON | 1,327 (1.0) | 0 | 1 | 78.6 (14.7) | - | - |
UB HN | 371 (0.3) | 0 | 1 | 79 (10.5) | - | - |
In situ carcinoma | 187 (0.1) | 0 | 1 | 73.4 (12.4) | - | - |